Invivyd

Yahoo Finance • 5 days ago

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW HAVEN, Conn., May 05, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on May 1, 2026, Invivyd granted 17 newly hired non-executive employees options to purchase an aggregate of 731,000 shares of its common... Full story

Yahoo Finance • last month

Invivyd rises after update from late-stage trial for COVID therapy

[Corona Virus covid-19 illustration] peterschreiber.media Invivyd (IVVD [https://seekingalpha.com/symbol/IVVD]) shares rose on Thursday after the Waltham, Massachusetts-based biotech announced progress in a late-stage trial for VYD2311, i... Full story

Yahoo Finance • last month

Invivyd Launches “Antibodies for Any Body” in Partnership with World Champion Skier Lindsey Vonn to Inspire Actions that Help Support Immune Health

National education campaign aims to educate Americans about antibodies and their role in immune healthCampaign centerpiece, AntibodiesforAnyBody.com, offers an interactive immune health wellnessassessment to empower people to better unders... Full story

Yahoo Finance • last month

Invivyd Announces Presentation at the World Vaccine Congress Washington

Chief Scientific Officer, Robert Allen, Ph.D., presented as part of the “Antibodies for Infectious Disease Workshop” at the World Vaccine Congress WashingtonPresentation titled “Developing mAb Therapies that Keep Pace with Rapidly Evolving... Full story

Yahoo Finance • 4 months ago

BTIG Initiates Invivyd (IVVD) Coverage, Cites VYD2311’s Superior Market Potential Over Pemgarda

Invivyd Inc. (NASDAQ:IVVD) is one of the best biotech penny stocks to buy according to analysts. On December 22, BTIG analyst Thomas Shrader initiated coverage of Invivyd with a Buy rating and $10 price target. BTIG maintained this stance... Full story

Yahoo Finance • 4 months ago

Does Invivyd’s (IVVD) Index Debut Reveal a Turning Point in Its Biotech Credibility?

Invivyd, Inc. was recently added to both the NASDAQ Biotechnology Index and the S&P Biotechnology Select Industry Index, increasing its presence among publicly traded biotech peers. This twin index inclusion can broaden Invivyd’s exposure... Full story

Yahoo Finance • 5 months ago

Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

NEW HAVEN, Conn., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for VYD2311, an investigational vaccine-alternative mono... Full story

Yahoo Finance • 5 months ago

Invivyd to Participate at the 8th Annual Evercore Healthcare Conference

NEW HAVEN, Conn., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that management will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025, at 2:35 p... Full story

Yahoo Finance • 5 months ago

Invivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND Readiness

VBY329 is designed for the prevention of Respiratory Syncytial Virus (RSV) infections in newborns, infants, and children, and results from Invivyd’s proprietary antibody discovery technology platformVBY329 meets Invivyd’s target profile of... Full story

Yahoo Finance • 6 months ago

Invivyd prices $125M stock offering at $2.50 per share

* Invivyd (IVVD [https://seekingalpha.com/symbol/IVVD]) priced [https://seekingalpha.com/pr/20310672-invivyd-announces-pricing-of-125-million-public-offering-of-common-stock-and-pre-funded] an underwritten public offering of 44M shares a... Full story

Yahoo Finance • 6 months ago

Invivyd Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded Warrants

NEW HAVEN, Conn., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Invivyd) (Nasdaq: IVVD) today announced the pricing of an underwritten public offering of 44,000,000 shares of its common stock at an offering price of $2.50 per share an... Full story

Yahoo Finance • 6 months ago

Invivyd Announces Proposed Public Offering of Common Stock

NEW HAVEN, Conn., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Invivyd) (Nasdaq: IVVD) today announced that it has commenced an underwritten public offering of shares of its common stock. In addition, Invivyd intends to grant the und... Full story

Yahoo Finance • 6 months ago

BC-Most Active Stocks

NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks: Stock Name Volume High Low Last Change UTime Ltd. 897,372,188 0.045 0.035 0.0365 +0.0165 Aspire Biopharma Holdi... Full story

Yahoo Finance • 6 months ago

Invivyd Reports Third Quarter 2025 Financial Results and Recent Business Highlights

PEMGARDA® (pemivibart) net product revenue of $13.1 million reported for Q3 2025, representing 41% growth year-over-year and 11% growth quarter-over-quarterOctober 2025 ending cash and cash equivalents of over $100 million; ended Q3 2025 w... Full story

Yahoo Finance • 6 months ago

Invivyd to Host Webcast on the REVOLUTION Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

NEW HAVEN, Conn., Oct. 28, 2025 (GLOBE NEWSWIRE) -- WHAT: Invivyd, Inc. (Nasdaq: IVVD) is hosting the previously announced live webcast to present an overview of the company’s REVOLUTION clinical program, Invivyd’s development program f... Full story

Yahoo Finance • 7 months ago

Invivyd Gets FDA Clearance To Start Clinical Trials For COVID-19 Antibody VYD2311

(RTTNews) - Invivyd, Inc. (IVVD) Monday announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for VYD2311, a vaccine alternative antibody candidate for the preventi... Full story

Yahoo Finance • 7 months ago

Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

The DECLARATION (safety and efficacy vs. placebo) and LIBERTY (exploratory safety head-to-head and combination with mRNA-based COVID vaccination) clinical trials are expected to begin around year-end 2025; top-line data anticipated mid-202... Full story

Yahoo Finance • 7 months ago

Invivyd Appoints Paul B. Bolno, M.D. to Its Board of Directors

NEW HAVEN, Conn., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ: IVVD) today announced the appointment of Paul B. Bolno, M.D., to its Board of Directors and as a member of the Compensation Committee. Dr. Bolno is the President... Full story

Yahoo Finance • 8 months ago

Invivyd Announces Appointment of Kristie Kuhl as Chief Communications Officer

NEW HAVEN, Conn., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced the appointment of Kristie Kuhl as Chief Communications Officer. Ms. Kuhl will lead the Company’s communications and patient advocacy effor... Full story

Yahoo Finance • 8 months ago

These stocks are moving in today's after hours session

After the closing bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session. [postmarket] GAINERS TICKER CHANGE COMMENT CHEK [https://www.chartmill.com/stock/... Full story